Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "|Not reportedAS" to "|NRAS") |
||
(5 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
− | From the [ | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=653635 NCI Drug Dictionary]: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. |
− | ==Diseases for which it is | + | ==Diseases for which it is established== |
− | *[[Colorectal cancer, BRAF-mutated]] | + | *[[Colorectal cancer, BRAF-mutated|BRAF-mutant colorectal cancer]] |
*[[Melanoma,_BRAF-mutated|BRAF-mutant melanoma]] | *[[Melanoma,_BRAF-mutated|BRAF-mutant melanoma]] | ||
+ | *[[Non-small cell lung cancer, BRAF-mutated|BRAF-mutant NSCLC]] | ||
*[[Melanoma,_NRAS-mutated|NRAS-mutant melanoma]] | *[[Melanoma,_NRAS-mutated|NRAS-mutant melanoma]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2018-06-27: Initial FDA approval in combination with [[Encorafenib (Braftovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. ''(Based on COLUMBUS)'' | *2018-06-27: Initial FDA approval in combination with [[Encorafenib (Braftovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. ''(Based on COLUMBUS)'' | ||
+ | *2023-10-11: Approved with [[Encorafenib (Braftovi)]] for adult patients with metastatic [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] with a BRAF V600E mutation, as detected by an FDA-approved test. ''(Based on PHAROS)'' | ||
+ | |||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
− | *2018-09-20: Initial authorization as Mektovi. Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic [[melanoma]] with a BRAF V600 mutation. ''(Based on COLUMBUS and LOGIC 2)'' | + | *2018-09-20: Initial authorization as Mektovi. Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic [[melanoma]] with a BRAF V600 mutation. ''(Based on COLUMBUS and LOGIC-2)'' |
*2020-04-30: Extension of indication to include encorafenib in combination with cetuximab, for the treatment of adult patients with metastatic [[colorectal cancer|colorectal cancer (CRC)]] with a BRAF V600E mutation, who have received prior systemic therapy. | *2020-04-30: Extension of indication to include encorafenib in combination with cetuximab, for the treatment of adult patients with metastatic [[colorectal cancer|colorectal cancer (CRC)]] with a BRAF V600E mutation, who have received prior systemic therapy. | ||
+ | |||
==History of changes in Health Canada indication== | ==History of changes in Health Canada indication== | ||
*2021-03-02: Initial notice of compliance in combination with encorafenib for the treatment of patients with unresectable or metastatic [[melanoma]] with a BRAF V600 mutation, as detected by a validated test. | *2021-03-02: Initial notice of compliance in combination with encorafenib for the treatment of patients with unresectable or metastatic [[melanoma]] with a BRAF V600 mutation, as detected by a validated test. | ||
Line 30: | Line 34: | ||
[[Category:Colorectal cancer medications]] | [[Category:Colorectal cancer medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
+ | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:EMA approved in 2018]] | [[Category:EMA approved in 2018]] |
Latest revision as of 01:03, 23 July 2024
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Diseases for which it is established
History of changes in FDA indication
- 2018-06-27: Initial FDA approval in combination with Encorafenib (Braftovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Based on COLUMBUS)
- 2023-10-11: Approved with Encorafenib (Braftovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Based on PHAROS)
History of changes in EMA indication
- 2018-09-20: Initial authorization as Mektovi. Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. (Based on COLUMBUS and LOGIC-2)
- 2020-04-30: Extension of indication to include encorafenib in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.
History of changes in Health Canada indication
- 2021-03-02: Initial notice of compliance in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.
History of changes in PMDA indication
- 2019-01-08: New approval for the treatment of unresectable melanoma with BRAF gene mutation.
- 2020-11-27: New indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive colorectal cancer that has progressed after cancer chemotherapy.
Also known as
- Code names: ARRY-162, ARRY-438162, MEK-162
- Brand names: Mektovi